- •Preface and Acknowledgments
- •Contents
- •Contributors
- •1: Embryology for Urologists
- •Introduction
- •Renal Development
- •Pronephros
- •Mesonephros
- •Metanephros
- •Development of the Collecting System
- •Critical Steps in Further Development
- •Anomalies of the Kidney
- •Renal Agenesis
- •Renal Aplasia
- •Renal Hypoplasia
- •Renal Ectopia
- •Renal Fusion
- •Ureteral Development
- •Anomalies of Origin
- •Anomalies of Number
- •Incomplete Ureteral Duplication
- •Complete Ureteral Duplication
- •Ureteral Ectopia
- •Embryology of Ectopia
- •Clinical Correlation
- •Location of Ectopic Ureteral Orifices – Male (in Descending Order According to Incidence)
- •Symptoms
- •Ureteroceles
- •Congenital Ureteral Obstruction
- •Pipestem Ureter
- •Megaureter-Megacystis Syndrome
- •Prune Belly Syndrome
- •Vascular Ureteral Obstructions
- •Division of the Urogenital Sinus
- •Bladder Development
- •Urachal Anomalies
- •Cloacal Duct Anomalies
- •Other Bladder Anomalies
- •Bladder Diverticula
- •Bladder Extrophy
- •Gonadal Development
- •Testicular Differentiation
- •Ovarian Differentiation
- •Gonadal Anomalies
- •Genital Duct System
- •Disorders of Testicular Function
- •Female Ductal Development
- •Prostatic Urethral Valves
- •Gonadal Duct Anomalies
- •External Genital Development
- •Male External Genital Development
- •Female External Genital Development
- •Anomalies of the External Genitalia
- •References
- •2: Gross and Laparoscopic Anatomy of the Upper Urinary Tract and Retroperitoneum
- •Overview
- •The Kidneys
- •The Renal Vasculature
- •The Renal Collecting System
- •The Ureters
- •Retroperitoneal Lymphatics
- •Retroperitoneal Nerves
- •The Adrenal Glands
- •References
- •3: Gross and Laparoscopic Anatomy of the Lower Urinary Tract and Pelvis
- •Introduction
- •Female Pelvis
- •Male Pelvis
- •Pelvic Floor
- •Urinary Bladder
- •Urethra
- •Male Urethra
- •Female Urethra
- •Sphincter Mechanisms
- •The Bladder Neck Component
- •The Urethral Wall Component
- •The External Urethral Sphincter
- •Summary
- •References
- •4: Anatomy of the Male Reproductive System
- •Testis and Scrotum
- •Spermatogenesis
- •Hormonal Regulation of Spermatogenesis
- •Genetic Regulation of Spermatogenesis
- •Epididymis and Ductus Deferens
- •Accessory Sex Glands
- •Prostate
- •Seminal Vesicles
- •Bulbourethral Glands
- •Penis
- •Erection and Ejaculation
- •References
- •5: Imaging of the Upper Tracts
- •Anatomy of the Upper Tracts and Introduction to Imaging Modalities
- •Introduction
- •Renal Upper Tract Basic Anatomy
- •Modalities Used for Imaging the Upper Tracts
- •Ultrasound
- •Radiation Issues
- •Contrast Issues
- •Renal and Upper Tract Tumors
- •Benign Renal Tumors
- •Transitional Cell Carcinoma
- •Renal Mass Biopsy
- •Renal Stone Disease
- •Ultrasound
- •Plain Radiographs and IVU
- •Renal Cystic Disease
- •Benign Renal Cysts
- •Hereditary Renal Cystic Disease
- •Complex Renal Cysts
- •Renal Trauma
- •References
- •Introduction
- •Pathophysiology
- •Susceptibility and Resistance
- •Epidemiological Breakpoints
- •Clinical Breakpoints
- •Pharmacodynamic Parameters
- •Pharmacokinetic Parameters
- •Fosfomycin
- •Nitrofurantoin
- •Pivmecillinam
- •b-Lactam-Antibiotics
- •Penicillins
- •Cephalosporins
- •Carbapenems
- •Aminoglycosides
- •Fluoroquinolones
- •Trimethoprim, Cotrimoxazole
- •Glycopeptides
- •Linezolid
- •Conclusion
- •References
- •7: An Overview of Renal Physiology
- •Introduction
- •Body Fluid Compartments
- •Regulation of Potassium Balance
- •Regulation of Acid–Base Balance
- •Diuretics
- •Suggested Reading
- •8: Ureteral Physiology and Pharmacology
- •Ureteral Anatomy
- •Modulation of Peristalsis
- •Ureteral Pharmacology
- •Conclusion
- •References
- •Introduction
- •Afferent Signaling Pathways
- •Efferent Signaling
- •Parasympathetic Nerves
- •Sympathetic Nerves
- •Vesico-Spinal-Vesical Micturition Reflex
- •Peripheral Targets
- •Afferent Signaling Mechanisms
- •Urothelium
- •Myocytes
- •Cholinergic Receptors
- •Muscarinic Receptors
- •Nicotinic Receptors
- •Adrenergic Receptors (ARs)
- •a-Adrenoceptors
- •b-Adrenoceptors
- •Transient Receptor Potential (TRP) Receptors
- •Phosphodiesterases (PDEs)
- •CNS Targets
- •Opioid Receptors
- •Serotonin (5-HT) Mechanisms
- •g-Amino Butyric Acid (GABA) Mechanisms
- •Gabapentin
- •Neurokinin and Neurokinin Receptors
- •Summary
- •References
- •10: Pharmacology of Sexual Function
- •Introduction
- •Sexual Desire/Arousal
- •Endocrinology
- •Steroids in the Male
- •Steroids in the Female
- •Neurohormones
- •Neurotransmitters
- •Dopamine
- •Serotonin
- •Pharmacological Strategies
- •CNS Drugs
- •Enzyme-inducing Antiepileptic Drugs
- •Erectile Function
- •Ejaculatory Function
- •Premature Ejaculation
- •Abnormal Ejaculation
- •Conclusions
- •References
- •Epidemiology
- •Calcium-Based Urolithiasis
- •Uric Acid Urolithiasis
- •Infectious Urolithiasis
- •Cystine-Based Urolithiasis
- •Aims
- •Who Deserves Metabolic Evaluation?
- •Metabolic Workup for Stone Producers
- •Medical History and Physical Examination
- •Stone Analysis
- •Serum Chemistry
- •Urine Evaluation
- •Urine Cultures
- •Urinalysis
- •Twenty-Four Hour Urine Collections
- •Radiologic Imaging
- •Medical Management
- •Conservative Management
- •Increased Fluid Intake
- •Citrus Juices
- •Dietary Restrictions
- •Restricted Oxalate Diet
- •Conservative Measures
- •Selective Medical Therapy
- •Absorptive Hypercalciuria
- •Thiazide
- •Orthophosphate
- •Renal Hypercalciuria
- •Primary Hyperparathyroidism
- •Hyperuricosuric Calcium Oxalate Nephrolithiasis
- •Enteric Hyperoxaluria
- •Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Distal Renal Tubular Acidosis
- •Chronic Diarrheal States
- •Thiazide-Induced Hypocitraturia
- •Idiopathic Hypocitraturic Calcium Oxalate Nephrolithiasis
- •Hypomagnesiuric Calcium Nephrolithiasis
- •Gouty Diathesis
- •Cystinuria
- •Infection Lithiasis
- •Summary
- •References
- •12: Molecular Biology for Urologists
- •Introduction
- •Inherited Changes in Cancer Cells
- •VEGR and Cell Signaling
- •Targeting mTOR
- •Conclusion
- •References
- •13: Chemotherapeutic Agents for Urologic Oncology
- •Introduction
- •Bladder Cancer
- •Muscle Invasive Bladder Cancer
- •Metastatic Bladder Cancer
- •Conclusion
- •Prostate Cancer
- •Other Chemotherapeutic Drugs or Combinations for Treating HRPC
- •Conclusion
- •Renal Cell Carcinoma
- •Chemotherapy
- •Immunotherapy
- •Angiogenesis Inhibitor Drugs
- •Conclusion
- •Testicular Cancer
- •Stage I Seminoma
- •Stage I non-seminomatous Germ Cell Tumours (NSGCT)
- •Metastatic Germ Cell Tumours
- •Low-Volume Metastatic Disease (Stage II A/B)
- •Advanced Metastatic Disease
- •Salvage Chemotherapy for Relapsed or Refractory Disease
- •Conclusion
- •Penile Cancer
- •Side Effects of Chemotherapy
- •Conclusion
- •References
- •14: Tumor and Transplant Immunology
- •Antibodies
- •Cytotoxic and T-helper Cells
- •Immunosuppression
- •Induction Therapy
- •Maintenance Therapy
- •Rejection
- •Posttransplant Lymphoproliferative Disease
- •Summary
- •References
- •15: Pathophysiology of Renal Obstruction
- •Causes of Renal Obstruction
- •Effects on Prenatal Development
- •Prenatal Hydronephrosis
- •Spectrum of Renal Abnormalities
- •Renal Functional Changes
- •Renal Growth/Counterbalance
- •Vascular Changes
- •Inflammatory Mediators
- •Glomerular Development Changes
- •Mechanical Stretch of Renal Tubules
- •Unilateral Versus Bilateral
- •Limitations of Animal Models
- •Future Research
- •Issues in Patient Management
- •Diagnostic Imaging
- •Ultrasound
- •Intravenous Urography
- •Antegrade Urography and the Whitaker Test
- •Nuclear Renography
- •Computed Tomography
- •Magnetic Resonance Urography
- •Hypertension
- •Postobstructive Diuresis
- •References
- •Introduction
- •The Normal Lower Urinary Tract
- •Anatomy
- •Storage Function
- •Voiding Function
- •Neural Control
- •Symptoms
- •Flow Rate and Post-void Residual
- •Voiding Cystometry
- •Male
- •Female
- •Neurourology
- •Conclusions
- •References
- •17: Urologic Endocrinology
- •The Testis
- •Normal Androgen Metabolism
- •Epidemiological Aspects
- •Prostate
- •Brain
- •Muscle Mass and Adipose Tissue
- •Bones
- •Ematopoiesis
- •Metabolism
- •Cardiovascular System
- •Clinical Assessment
- •Biochemical Assessment
- •Treatment Modalities
- •Oral Preparations
- •Parenteral Preparations
- •Transdermal Preparations
- •Side Effects and Treatment Monitoring
- •Body Composition
- •Cognitive Decline
- •Bone Metabolism
- •The Kidneys
- •Endocrine Functions of the Kidney
- •Erythropoietin
- •Calcitriol
- •Renin
- •Paraneoplastic Syndromes
- •Hypercalcemia
- •Hypertension
- •Polycythemia
- •Other Endocrine Abnormalities
- •References
- •General Physiology
- •Prostate Innervation
- •Summary
- •References
- •Wound Healing
- •Inflammation
- •Proliferation
- •Remodeling
- •Principles of Plastic Surgery
- •Tissue Characteristics
- •Grafts
- •Flap
- •References
- •Lower Urinary Tract Symptoms
- •Storage Phase
- •Voiding Phase
- •Return to Storage Phase
- •Urodynamic Parameters
- •Urodynamic Techniques
- •Volume Voided Charts
- •Pad Testing
- •Typical Test Schedule
- •Uroflowmetry
- •Post Voiding Residual
- •Further Diagnostic Evaluation of Patients
- •Cystometry with or Without Video
- •Cystometry
- •Videocystometrography (Cystometry + Cystourethrography)
- •Cystometric Findings
- •Comment:
- •Measurements During the Storage Phase:
- •Measurements During the Voiding Phase:
- •Abnormal Function
- •Disorders of Sensation
- •Causes of Hypersensitive Bladder Sensation
- •Causes of Hyposensitive Bladder Sensation
- •Disorders of Detrusor Motor Function
- •Bladder Outflow Tract Dysfunction
- •Detrusor–Urethral Dyssynergia
- •Detrusor–Bladder Neck Dyssynergia
- •Detrusor–Sphincter Dyssynergia
- •Complex Urodynamic Investigation
- •Urethral Pressure Measurement
- •Technique
- •Neurophysiological Evaluation
- •Conclusion
- •References
- •Endoscopy
- •Cystourethroscopy
- •Ureteroscopy and Ureteropyeloscopy
- •Nephroscopy
- •Virtual Reality Simulators
- •Lasers
- •Clinical Application of Lasers
- •Condylomata Acuminata
- •Urolithiasis
- •Benign Prostatic Hyperplasia
- •Ureteral and Urethral Strictures
- •Conclusion
- •References
- •Introduction
- •The Prostatitis Syndromes
- •The Scope of the Problem
- •Category III CP/CPPS
- •The Goal of Treatment
- •Conservative Management
- •Drug Therapy
- •Antibiotics
- •Anti-inflammatories
- •Alpha blockers
- •Hormone Therapies
- •Phytotherapies
- •Analgesics, muscle relaxants and neuromodulators
- •Surgery
- •A Practical Management Plan
- •References
- •Orchitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment of Infectious Orchitis
- •Epididymitis
- •Definition and Etiology
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation of Epididymitis
- •Treatment of Acute Epididymitis
- •Treatment of Chronic Epididymitis
- •Treatment of Spermatic Cord Torsion
- •Fournier’s Gangrene
- •Definition and Etiology
- •Risk Factors
- •Clinical Signs and Symptoms
- •Diagnostic Evaluation
- •Treatment
- •References
- •Fungal Infections
- •Candidiasis
- •Aspergillosis
- •Cryptococcosis
- •Blastomycosis
- •Coccidioidomycosis
- •Histoplasmosis
- •Radiographic Findings
- •Treatment
- •Tuberculosis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Schistosomiasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Filariasis
- •Clinical Manifestations
- •Diagnosis
- •Treatment
- •Onchocerciasis
- •References
- •25: Sexually Transmitted Infections
- •Introduction
- •STIs Associated with Genital Ulcers
- •Herpes Simplex Virus
- •Diagnosis
- •Treatment
- •Chancroid
- •Diagnosis
- •Treatment
- •Syphilis
- •Diagnosis
- •Treatment
- •Lymphogranuloma Venereum
- •Diagnosis
- •Treatment
- •Chlamydia
- •Diagnosis
- •Treatment
- •Gonorrhea
- •Diagnosis
- •Treatment
- •Trichomoniasis
- •Diagnosis
- •Treatment
- •Human Papilloma Virus
- •Diagnosis
- •Treatment
- •Scabies
- •Diagnosis
- •Treatment
- •References
- •26: Hematuria: Evaluation and Management
- •Introduction
- •Classification of Hematuria
- •Macroscopic Hematuria
- •Microscopic Hematuria
- •Dipstick Hematuria
- •Pseudohematuria
- •Factitious Hematuria
- •Menstruation
- •Aetiology
- •Malignancy
- •Urinary Calculi
- •Infection and Inflammation
- •Benign Prostatic Hyperplasia
- •Trauma
- •Drugs
- •Nephrological Causes
- •Assessment
- •History
- •Examination
- •Investigations
- •Dipstick Urinalysis
- •Cytology
- •Molecular Tests
- •Blood Tests
- •Flexible Cystoscopy
- •Upper Urinary Tract Evaluation
- •Renal USS
- •KUB Abdominal X-Ray
- •Intravenous Urography (IVU)
- •Computed Tomography (CT)
- •Retrograde Urogram Studies
- •Magnetic Resonance Imaging (MRI)
- •Additional Tests and Renal Biopsy
- •Intractable Hematuria
- •Loin Pain Hematuria Syndrome
- •References
- •27: Benign Prostatic Hyperplasia (BPH)
- •Historical Background
- •Pathophysiology
- •Patient Assessment
- •Treatment of BPH
- •Watchful Waiting
- •Drug Therapy
- •Interventional Therapies
- •Conclusions
- •References
- •28: Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie´s Disease
- •Erectile Dysfunction
- •Introduction
- •Diagnosis
- •Basic Evaluation
- •Cardiovascular System and Sexual Activity
- •Optional Tests
- •Treatment
- •Medical Treatment
- •Oral Agents
- •Phosphodiesterase Type 5 (PDE 5) Inhibitors
- •Nonresponders to PDE5 Inhibitors
- •Apomorphine SL
- •Yohimbine
- •Intracavernosal and Intraurethral Therapy
- •Intracavernosal Injection (ICI) Therapy
- •Intraurethral Therapy
- •Vacuum Constriction Devices
- •Surgical Therapy
- •Conclusion
- •Peyronie´s Disease (PD)
- •Introduction
- •Oral Drug Therapy
- •Intralesional Drug Therapy
- •Iontophoresis
- •Radiation Therapy
- •Surgical Therapy
- •References
- •29: Premature Ejaculation
- •Introduction
- •Epidemiology
- •Defining Premature Ejaculation
- •Voluntary Control
- •Sexual Satisfaction
- •Distress
- •Psychosexual Counseling
- •Pharmacological Treatment
- •On-Demand Treatment with Tramadol
- •Topical Anesthetics
- •Phosphodiesterase Inhibitors
- •Surgery
- •Conclusion
- •References
- •30: The Role of Interventional Management for Urinary Tract Calculi
- •Contraindications to ESWL
- •Complications of ESWL
- •PCNL Access
- •Instrumentation for PCNL
- •Nephrostomy Drains Post PCNL
- •Contraindications to PCNL
- •Complications of PCNL
- •Semirigid Ureteroscopy
- •Flexible Ureteroscopy
- •Electrohydraulic Lithotripsy (EHL)
- •Ultrasound
- •Ballistic Lithotripsy
- •Laser Lithotripsy
- •Ureteric Stents
- •Staghorn Calculi
- •Lower Pole Stones
- •Horseshoe Kidneys and Stones
- •Calyceal Diverticula Stones
- •Stones and PUJ Obstruction
- •Treatment of Ureteric Colic
- •Medical Expulsive Therapy (MET)
- •Intervention for Ureteric Stones
- •Stones in Pregnancy
- •Morbid Obesity
- •References
- •Anatomy and Function
- •Pathophysiology
- •Management
- •Optical Urethrotomy/Dilatation
- •Urethral Stents
- •Preoperative Assessment
- •Urethroplasty
- •Anastomotic Urethroplasty
- •Substitution Urethroplasty
- •Grafts Versus Flaps
- •Oral Mucosal Grafts
- •Tissue Engineering
- •Graft Position
- •Conclusion
- •References
- •32: Urinary Incontinence
- •Epidemiology and Risk Factors
- •Pathophysiology
- •Urge Incontinence
- •Conservative Treatments
- •Pharmacotherapy
- •Invasive/ Surgical Therapies
- •Stress Urinary Incontinence
- •Male SUI Therapies
- •Female SUI Therapies
- •Mixed Urinary Incontinence
- •Conclusions
- •References
- •33: Neurogenic Bladder
- •Introduction
- •Examination and Diagnostic Tests
- •History and Physical Examination
- •Imaging
- •Urodynamics (UDS)
- •Evoked Potentials
- •Classifications
- •Somatic Pathways
- •Brain Lesions
- •Cerebrovascular Accident (CVA)
- •Parkinson’s Disease (PD)
- •Multiple Sclerosis
- •Huntington’s Disease
- •Dementias
- •Normal Pressure Hydrocephalus (NPH)
- •Tumors
- •Psychiatric Disorders
- •Spinal Lesions and Pathology
- •Intervertebral Disk Prolapse
- •Spinal Cord Injury (SCI)
- •Transverse Myelitis
- •Peripheral Neuropathies
- •Metabolic Neuropathies
- •Pelvic Surgery
- •Treatment
- •Summary
- •References
- •34: Pelvic Prolapse
- •Introduction
- •Epidemiology
- •Anatomy and Pathophysiology
- •Evaluation and Diagnosis
- •Outcome Measures
- •Imaging
- •Urodynamics
- •Indications for Management
- •Biosynthetics
- •Surgical Management
- •Anterior Compartment Repair
- •Uterine/Apical Prolapse
- •Enterocele Repair
- •Conclusion
- •References
- •35: Urinary Tract Fistula
- •Introduction
- •Urogynecologic Fistula
- •Vesicovaginal Fistula
- •Etiology and Risk Factors
- •Clinical Factors
- •Evaluation and Diagnosis
- •Pelvic Examination
- •Cystoscopy
- •Imaging
- •Treatment
- •Conservative Management
- •Surgical Management
- •Urethrovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Ureterovaginal Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Vesicouterine Fistula
- •Etiology and Presentation
- •Diagnosis and Management
- •Uro-Enteric Fistula
- •Vesicoenteric Fistula
- •Pyeloenteric Fistula
- •Urethrorectal Fistula
- •References
- •36: Urologic Trauma
- •Introduction
- •Kidney
- •Expectant Management
- •Endovascular Therapy
- •Operative Intervention
- •Operative Management: Follow-up
- •Reno-Vascular Injuries
- •Pediatric Renal Injuries
- •Adrenal
- •Ureter
- •Diagnosis
- •Treatment
- •Delayed Diagnosis
- •Bladder and Posterior Urethra
- •Bladder Injuries: Initial Management
- •Bladder Injuries: Formal Repair
- •Anterior Urethral Trauma
- •Fractured Penis
- •Penile Amputation
- •Scrotal and Testicular Trauma
- •Imaging
- •CT-IVP (CT with Delayed Images)
- •Technique
- •Cystogram
- •Technique
- •Retrograde Urethrogram (RUG)
- •Technique
- •Retrograde Pyelogram (RPG)
- •Technique
- •One-Shot IVP
- •Technique
- •References
- •37: Bladder Cancer
- •Who Should Be Investigated?
- •Epidemiology
- •Risk Factors
- •Role of Screening
- •Signs and Symptoms
- •Imaging
- •Cystoscopy
- •Urine Tests
- •PDD-Assisted TUR
- •Pathology
- •NMIBC and Risk Groups
- •Intravesical Chemotherapy
- •Intravesical Immunotherapy
- •Immediate Cystectomy and CIS
- •Radical Cystectomy with Pelvic Lymph Node Dissection
- •sexual function-preserving techniques
- •Bladder-Preservation Treatments
- •Neoadjuvant Chemotherapy
- •Adjuvant Chemotherapy
- •Preoperative Radiotherapy
- •Follow-up After TUR in NMIBC
- •References
- •38: Prostate Cancer
- •Introduction
- •Epidemiology
- •Race
- •Geographic Variation
- •Risk Factors and Prevention
- •Family History
- •Diet and Lifestyle
- •Prevention
- •Screening and Diagnosis
- •Current Screening Recommendations
- •Biopsy
- •Pathology
- •Prognosis
- •Treatment of Prostate Cancer
- •Treatment for Localized Prostate Cancer (T1, T2)
- •Radical Prostatectomy
- •EBRT
- •IMRT
- •Brachytherapy
- •Treatment for Locally Advanced Prostate Cancer (T3, T4)
- •EBRT with ADT
- •Radical Prostatectomy
- •Androgen-Deprivation Therapy
- •Summary
- •References
- •39: The Management of Testis Cancer
- •Presentation and Diagnosis
- •Serum Tumor Markers
- •Primary Surgery
- •Testis Preserving Surgery
- •Risk Stratification
- •Surveillance Versus Primary RPLND
- •Primary RPLND
- •Adjuvant Treatment for High Risk
- •Clinical Stage 1 Seminoma
- •Risk-Stratified Adjuvant Treatment
- •Adjuvant Radiotherapy
- •Adjuvant Low Dose Chemotherapy
- •Primary Combination Chemotherapy
- •Late Toxicity
- •Salvage Strategies
- •Conclusion
- •References
- •Index
287
Urologic instrUmEntation: EndoscoPEs and lasErs
cause light to travel in all directions within the |
The wavelength of the laser of the tissue |
||||
laser cavity. Different laser source mediums |
and characteristics impact the laser effect. |
||||
emit photons in different distinct wavelengths. |
Hemoglobin and water absorb light at different |
||||
Laser light differs from natural light in that it |
wavelengths. These interactions result in differ- |
||||
must have photons in phase, known as coher- |
ent degrees of depth of penetration, absorption, |
||||
ence, they must travel in parallel, known as col- |
reflection, and scattering of laser energy. In |
||||
limation,and all must have the same wavelength |
addition, the denser the tissue is or becomes |
||||
or color in the visible light spectrum, known as |
during treatment, the greater the degree of |
||||
monochromaticity. These properties allow the |
absorption of light energy and the transforma- |
||||
laser light to be targeted accurately and with |
tion to heat, resulting in decreasing penetration |
||||
very high intensity.15 |
|
into tissue. Blood flow also acts as a sink to |
|||
The performance of a laser is based on the |
absorb thermal energy, thus reducing the power |
||||
power output and the mode of emission. Three |
of the laser at the site of action.15 |
||||
types of lasers are important in clinical urologic |
There are many different types of lasers that |
||||
surgery. Continuous wave lasers emit a steady- |
are used by urologists. Lasers are named after |
||||
state beam. Pulsed lasers produce higher peak |
the laser medium generating a specific wave- |
||||
power than continuous as power output is built |
length. The section below focuses on the differ- |
||||
up between pulses. This allows for more precise |
ent lasers and their applications to treat urologic |
||||
control and less lateral heat conduction, and |
diseases: condylomata acuminata, urolithiasis, |
||||
pulsed lasers are commonly used for tissue |
benign prostatic hyperplasia, and ureteral and |
||||
coagulation.ThethirdtypeistermedQ-switched, |
urethral strictures. Table 21.1 describes a guide |
||||
a pulsing technique that produces high-peak |
to lasers and their applications. |
||||
power output for short duration.15 |
|
|
|
|
|
There are 4 physical properties of a laser, |
Clinical Application of Lasers |
||||
which impacts the type of laser used for differ- |
|||||
ent procedures. Energy is the amount of work |
Condylomata Acuminata |
|
|||
produced (Joules). Rate is described as cycles/s |
|
||||
(Hertz). Power is the rate of energy expenditure |
The CO2 laser is often used to treat condylomata |
||||
(measured in Watts = Joules/s). Fluence is the |
|||||
acuminata on the skin or urethral meatus. This |
|||||
amount of energy delivered per unit |
area |
||||
laser emits light |
in the far infrared portion |
||||
(J/cm2), which determines the magnitude of the |
|||||
(10,600 nm) and has a very short extinction |
|||||
lasers interaction on the tissue. Thus, the smaller |
|||||
length. Absorption of energy at the surgical site |
|||||
the area, the more energy delivered to the tissue. |
|||||
causes thermal coagulation to a depth of approx- |
|||||
Irradiance or power density is the intensity of |
|||||
imately 0.5 mm. Infected epithelium from the |
|||||
the laser beam (W/cm2) and plays a critical role |
|||||
papillomavirus (HPV) should be ablated pre- |
|||||
in determining tissue interaction. |
|
||||
|
cisely to a shallow depth, so that the virus is |
||||
Tissue interaction can be classified as either |
|||||
killed and rapid |
healing |
can occur.16 Most |
|||
electromechanical, photoablative, photochemi- |
|||||
patients can be |
effectively |
treated with low |
|||
cal, or photothermal. Electromechanical causes |
|||||
morbidity. |
|
|
|||
dielectric breakdown in tissue by shock wave |
|
|
|||
|
|
|
|||
plasma expansion resulting in localized mechan- |
|
|
|
||
ical rupture. Urologists employ the electrome- |
Urolithiasis |
|
|
||
chanical property of laser energy for stone |
|
|
|||
|
|
|
|||
fragmentation by spallation and cavitation.15 |
Endoscopic laser lithotripsy is the most com- |
||||
Photoablative causes photodissociation |
or |
mon intracorporeal procedures performed by |
|||
breaking of molecular bonds in tissue. Photo- |
urologists to treat urolithiasis. Pulsed lasers are |
||||
chemical causes light-induced chemical reac- |
effective in stone fragmentation by producing |
||||
tions to destroy tissue. Finally, photothermal |
high power density at the stone surface with |
||||
converts light energy into heat energy causing |
minimized heat dissipation. The pulsed laser |
||||
tissue heating and vaporizing. Surgeons com- |
causes the release of electrons and the forma- |
||||
monly use the thermal effect of laser energy to |
tion of “plasma” bubbles, which then collapse |
||||
incise, coagulate or ablate tissues and fragment |
generating a shockwave.17 The first pulsed laser |
||||
calculi. |
|
for lithotripsy was the coumarin green dye |
288
Practical Urology: EssEntial PrinciPlEs and PracticE
Table 21.1. lasers |
|
|
|
|
|
Carbon dioxide |
KTP |
Nd:YAG |
Holmium:YAG |
|
|
Nd:YAG |
|
|
Wavelength (nm) |
10,600 |
532 |
1,064 |
2,140 |
depth of tissue penetration (mm) |
0.5 |
1–3 |
10 |
0.5 |
absorption |
Water |
Hemoglobin |
neither hemoglobin/ |
Water |
|
|
|
water |
|
irrigant |
Water |
saline/water |
saline/water |
saline |
mode of delivery |
continuous/pulsed |
continuous |
continuous/pulsed |
Pulsed |
stone disease |
na |
na |
na |
a |
Prostate coagulation and incision |
na |
a |
a |
a |
stricture disease |
na |
a |
a |
a |
condyloma accuminata |
a |
na |
a |
a |
NA not applicable, A applicable |
|
|
|
|
medium. Coumarin’s wavelength is 504 nm and was absorbed by many stone materials, but not absorbed by the surrounding tissues.18 Thus, high energies could be used without causing injury to urothelial tissue. Stone composition affected absorption and the efficacy of the coumarin laser.For example,calcium oxalate monohydrate (COM) stones were difficult to fragment. The 200-micron fiber, which allowed for the greatest deflection, could generate only 80 J of coumarin laser energy, which was insufficient to fragment these dense stones. In addition, the coumarin dye laser was ineffective in fragmenting cystine stones. The coumarin laser took approximately 20 min to function and required eye protection with amber glass making visibility difficult.19
Today, the most common and most effective laser in the treatment of stones is the Holmium:YAG laser. It is delivered in a pulsatile manner at a wavelength of 2140 nm, which is highly absorbed by water. The holmium laser vaporizes water inside and on the surface of the stone, creating a vaporization or cavitation bubble. The cavitation bubble generates a shock wave, which destabilizes and fragments the stone, by a photothermal mechanism.20,21 The long pulse duration of 250–350 ms and pulse power of 0.25–2.5 KW produce an elongated cavitation bubble, which generates a weaker shockwave. This reduces the likelihood of retropulsion of the stones, while adequately fragmenting the stone.22
Several characteristics of the holmium laser make it both effective and versatile for intracorporeal lithotripsy and tissue treatment. The wavelength can be transmitted through quartz optical fibers making it useful for endoscopic surgery. The pulse duration and power of the holmium laser causes excellent stone fragmentation of all types of stones regardless of composition and can incise tissue at higher energy settings. Multiple fibers are available for endoscopic use, including the 200, 365, 500, and 1,000 mm laser fiber. A 200 or 365 mm laser fiber can be passed via a flexible ureteroscope facilitating intracorporeal lithotripsy throughout the entire collecting system.A side-firing fiber is also available for use in the bladder and for prostatic treatments (discussed below). The Holmium laser treatment of stones typically produces very small fragments and dust particles, which are less likely to obstruct the ureter traveling out of the collecting system and there is often less need to basket the fragments. Furthermore, the Holmium laser is extremely safe and causes less injury than other lithotrites (like EHL) to the ureter, unless directly applied to the tissue.
The zone of thermal injury is approximately 0.5–1.0 mm. Thus, the holmium laser is safely activated at a distance of 0.5–1 mm away from the ureteral wall.23 Unlike the coumarin pulseddye laser, eye protection does not compromise visibility because at levels typically used, the effect on the cornea at a distance from the laser of greater than 10 cm is minimal.24
289
Urologic instrUmEntation: EndoscoPEs and lasErs
Benign Prostatic Hyperplasia |
continuous flow resectoscope. Eye protection is |
|
necessary to filter the harmful radiation emitted |
The use of lasers for the treatment of benign |
from the KTP laser. |
prostatic hyperplasia (BPH) has cycled dramati- |
Gilling et al. are one of the first groups to |
cally over the past decade. The two mechanisms |
describe the technique of using the holmium |
by which lasers function to relieve the obstruc- |
laser to treat BPH.28 The Ho:YAG laser is highly |
tion caused by the adenoma are coagulation and |
absorbed by water and causes tissue vaporization. |
vaporization. Coagulative necrosis is caused by |
The laser can be used to either vaporize or enu- |
focused laser energy heating the tissue to tem- |
cleate the prostate. Advantages of the holmium |
peratures between 70°C and 100°C. Coagulation |
laser include its pulsed nature and minimal tissue |
may put tissues not being treated, like the |
penetration, which provides rapid tissue vapor- |
sphincter, at risk due to its imprecise mecha- |
ization, less tissue coagulation, and less injury to |
nism.Vaporization occurs at temperatures of up |
surrounding tissues.29 The laser has excellent |
to several 100°C. The power density is high, but |
hemostatic properties. Holmium laser ablation of |
it is delivered through a narrow beam, limiting |
the prostate (HoLAP) is performed with a 550- |
injury to surrounding tissues. |
mm side-firing laser fiber at 80–100 W power in a |
Initially, the Nd:YAG laser was used for coag- |
near-contact mode, creating a channel within the |
ulation of the prostate. The combination of neo- |
prostatic fossa.30 Contact with the tissue can cause |
dymium and yttrium aluminum garnet crystal |
overheating, which degrades the fiber tip and |
has high efficiency, increased rate of repetition, |
reduces the energy output. The procedure is eas- |
thermal conductivity, and good optical quality. |
ily learned, as it does not require resection and |
It emits light at 1,064 nm (poorly absorbed by |
retrieval of the tissue. Length of procedure is gen- |
both hemoglobin and water), which has a tissue |
erally dictated by prostatic size. Thus, HoLAP is |
penetration of 10 mm and causes deep coagula- |
best reserved for glands less than 50 g. |
tion and coagulative necrosis of the adenoma.15 |
Holmium laser enucleation of the prostate |
It can be used to coagulate up to 5 mm blood |
(HoLEP) is a minimally invasive alternative to |
vessels with hemostasis. Treatment of BPH with |
TURP and simulates the open simple prostatec- |
the Nd:YAG laser typically resulted in extended |
tomy. The prostate is divided into 3 anatomic |
periods of tissue sloughing and unacceptable |
lobes, the two lateral lobes and the median lobe. |
rates of irritative voiding symptoms and pro- |
The high-powered 100 W Holmium laser and a |
longed catheter time.25 The deep tissue penetra- |
550-mm end-firing holmium laser fiber are used |
tion of the Nd:YAG laser made it effective for |
to delineate the natural tissue plane between the |
BPH, but caused a high rate of tissue injury |
prostate adenoma and the prostatic capsule. |
when applied for lithotripsy. |
Once the three lobes are enucleated in a retro- |
An alternative technology is the potassium- |
grade fashion, morcellation is carried out to |
titanyl phosphate (KTP) “green light” laser, |
remove the tissue from the bladder.31 The main |
which utilizes the 1,064 nm Nd:YAG laser light |
advantage of the procedure is that the same |
that is emitted or passed through a KTP crystal |
amount of tissue is removed as with the open |
resulting in a green light.26 This laser technology |
simple prostatectomy but in a minimally inva- |
causes photoselective vaporization of the pros- |
sive technique. Multiple randomized controlled |
tate. The KTP crystal doubles the frequency and |
clinical trials comparing HoLEP to TURP and |
halves the wavelength to 532 nm, which is highly |
open simple prostatectomy have demonstrated |
absorbed by hemoglobin. This results in less |
HoLEP to have equal efficacy, improved AUA SS, |
depth of penetration (3 mm) as compared to the |
flow rates with shorter hospital stay, catheteriza- |
Nd:YAG laser (10 mm), which is much safer to |
tion time, and less blood loss.32,33 A disadvantage |
use in the prostatic cavity. In addition, it can be |
of the procedure has been the perception of a |
delivered at a higher power,either 80 W or 120 W |
challenging learning curve and translation of |
(new HPS system) maximizing the vaporization |
the technique to practicing community urolo- |
effect. The technique has decreased bleeding, |
gists, although Shah et al. have demonstrated |
making photoselective vaporization feasible in |
that an endourologist inexperienced in HoLEP |
patients on anticoagulation.27 Vaporization is |
can perform the procedure with reasonable effi- |
achieved through a side-firing laser in a near |
cacy after about 50 cases with comparable out- |
contact sweeping technique through a 24 F |
comes to that of experienced physician.34 |